Daniel Grima

2.2k citations

67 papers · 1.7k indexed · h-index 18

Impact in

Orthopedics and Sports Medicine top 5%
- Bone health and osteoporosis research
Epidemiology top 5%
- Cervical Cancer and HPV Research
- Hepatitis B Virus Studies

Papers in ⓘ

Economics and Econometrics 19
- Health Systems, Economic Evaluations, Quality of Life 18
- Pharmaceutical Economics and Policy 7
- Economic and Financial Impacts of Cancer 6
Epidemiology 11
- Hepatitis B Virus Studies 5

Co-authors: Milton C. Weinstein (3 shared papers)Thomas C. Wright (3 shared papers)Eduardo L. Franco (3 shared papers)Michele Kohli (3 shared papers)F. Xavier Bosch (1 shared paper)S. J. Goldie (2 shared papers)Sue J. Goldie (1 shared paper)Jonathan D. Adachi (5 shared papers)
Journals: Value in Health (18 papers)PharmacoEconomics (5 papers)Current Medical Research and Opinion (2 papers)Osteoporosis International (2 papers)Journal of Medical Economics (2 papers)
Partner nations: Canada United States United Kingdom

In The Last Decade

Daniel Grima

64 papers receiving 1.6k citations

Peers

Countries citing papers authored by Daniel Grima

Since Specialization

Citations

This map shows the geographic impact of Daniel Grima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Grima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Grima more than expected).

Fields of papers citing papers by Daniel Grima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Grima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Grima. The network helps show where Daniel Grima may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel Grima, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel Grima Line = papers co-authored together Daniel Grima links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 67 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine JNCI Journal of the National Cancer Institute ·S. J. Goldie, Michele Kohli, Daniel Grima, Milton C. Weinstein, Thomas C. Wright, F. Xavier Bosch, Eduardo L. Franco	2004	410
2	A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL Systematic Reviews ·Stephen Brown, Brian Hutton, Tammy Clifford, Doug Coyle, Daniel Grima, George A. Wells, Chris Cameron	2014	172
3	A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine International Journal of Cancer ·Sue J. Goldie, Daniel Grima, Michele Kohli, Thomas C. Wright, Milton C. Weinstein, Eduardo L. Franco	2003	171
4	Cost and health related quality of life consequences of multiple sclerosis Multiple Sclerosis Journal ·Daniel Grima, George W. Torrance, G. Francis, G Rice, Andrew Rosner, Louise Lafortune	2000	122
5	Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States Vox Sanguinis ·Deborah A. Marshall, Steven Kleinman, John B. Wong, James P. AuBuchon, Daniel Grima, Nathalie A. Kulin, Milton C. Weinstein	2004	115
6	Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis Nephrology Dialysis Transplantation ·Colin A. Hutchison, Nils Heyne, Parisa Airia, R Schindler, Daniel Zickler, Mark Cook, Paul Cockwell, Daniel Grima	2012	86
7	Challenges for Model-Based Economic Evaluations of Postmenopausal Osteoporosis Interventions Osteoporosis International ·Anna N.A. Tosteson, Bengt Jönsson, Daniel Grima, B. J. O’Brien, Dennis M. Black, Jonathan D. Adachi	2001	85
8	Modelling Cost Effectiveness of Insulin Glargine for the Treatment of Type 1 and 2 Diabetes in Canada PharmacoEconomics ·Daniel Grima, Melissa F Thompson, Luc Sauriol	2007	41
9	Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis PharmacoEconomics ·Daniel Grima, Lisa Bernard, Elizabeth S. Dunn, Philip A. McFarlane, David C. Mendelssohn	2012	39
10	Cost Effectiveness of Multi-Therapy Treatment Strategies in the Prevention of Vertebral Fractures in Postmenopausal Women with Osteoporosis PharmacoEconomics ·Andrew Rosner, Daniel Grima, George W. Torrance, Cathy J. Bradley, Jonathan D. Adachi, Rolf J. Sebaldt, Donald J. Willison	1998	28
11	Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study BMC Musculoskeletal Disorders ·Daniel Grima, Αλεξάνδρα Παπαϊωάννου, Parisa Airia, George Ioannidis, Jonathan D. Adachi	2010	25
12	Lack of Increased Colonization with Vancomycin-Resistant Enterococci during Preferential Use of Vancomycin for Treatment during an Outbreak of Healthcare-Associated Clostridium difficile Infection Infection Control and Hospital Epidemiology ·Mark A. Miller, Lisa Bernard, Melissa Thompson, Daniel Grima, Jocelyne Pépin	2010	23
13	Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone Bone Marrow Transplantation ·Anthony D. Sung, Daniel Grima, Lisa Bernard, Stephen Brown, George Carrum, Leona Holmberg, Mitchell E. Horwitz, Jane L. Liesveld, Junya Kanda, Brian McClune, Paul Shaughnessy, Guido Tricot, N J Chao	2013	23
14	Clinical and Economic Impacts of Latanoprost 0.005% in First-Line Treatment of Open-Angle Glaucoma and Ocular Hypertension in France European Journal of Ophthalmology ·Lisa Bernard, Rikard Althin, Ravinder Dhawan, Daniel Grima, Annette Lam, Samuel Aballéa	2003	22
15	Cost–Effectiveness of Combinatorial Pharmacogenomic Testing for Depression from the Canadian Public Payer Perspective Pharmacogenomics ·Julie‐Anne Tanner, Paige E. Davies, Christopher M. Overall, Daniel Grima, Julian Nam, Bryan Dechairo	2020	21
16	Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies European Heart Journal - Quality of Care and Clinical Outcomes ·Mark H. Rozenbaum, Andrea García, Daniel Grima, Diana Tran, Rahul Bhambri, Michelle Stewart, Benjamin Li, Bart Heeg, Maarten J. Postma, Ahmad Masri	2021	21
17	A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom Journal of Medical Economics ·Lisa Bernard, David C. Mendelssohn, Elizabeth S. Dunn, Colin A. Hutchison, Daniel Grima	2012	19
18	Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis Osteoporosis International ·Daniel Grima, Αλεξάνδρα Παπαϊωάννου, Melissa F Thompson, Margaret K. Pasquale, Jonathan D. Adachi	2007	18
19	Developing Better Economic Models of Osteoporosis: Considerations for the Calculation of the Relative Risk of Fracture Value in Health ·Dennis M. Black, Lisa Palermo, Daniel Grima	2006	17
20	Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada PharmacoEconomics - Open ·Moogeh Baharnoori, Virender Bhan, Fraser Clift, Kimberly Thomas, Soukaïna Mouallif, Nicholas Adlard, Philip Cooney, François Blanchette, Barkha P. Patel, Daniel Grima	2022	16

About Daniel Grima

Daniel Grima is a scholar working on Economics and Econometrics, Epidemiology, Molecular Biology, Surgery and Hematology, having authored 67 papers that have together received 1.7k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (18 papers), Pharmaceutical Economics and Policy (7 papers), Bone health and osteoporosis research (6 papers), Economic and Financial Impacts of Cancer (6 papers), Multiple Myeloma Research and Treatments (6 papers), Hepatitis B Virus Studies (5 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers) and Pharmacological Effects and Toxicity Studies (4 papers). The work is most often cited by research in Orthopedics and Sports Medicine (167 citations), Epidemiology (664 citations), Hematology (168 citations), Applied Microbiology and Biotechnology (24 citations) and Nephrology (75 citations). Daniel Grima has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Milton C. Weinstein, Thomas C. Wright, Eduardo L. Franco, Michele Kohli, F. Xavier Bosch, S. J. Goldie, Sue J. Goldie, Jonathan D. Adachi, Lisa Bernard and George A. Wells. Their work appears in journals such as Value in Health, PharmacoEconomics, Current Medical Research and Opinion, Osteoporosis International and Journal of Medical Economics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact